In the Claims:

The following listing of claims will replace any/all prior versions, and listings, of claims in the application:

Claim **1** (previously amended) A method of treating an individual suffering from incontinence, the method comprising the step of administering to the individual a therapeutically effective amount of a composition comprising a compound having a pharmacological selectivity of serotonin (K_i)/norepinephrine (K_i) of at least about 5000.

Claim **2** (original) The method of claim 1 wherein said composition is administered in an amount of about 0.1 to about 10 mg/day.

Claim **3** (original) The method of claim 2 wherein said composition is administered in an amount of about 0.5 to about 8 mg/day.

Claim **4** (original) The method of claim 3 wherein said composition is administered in an amount of about 0.5 to about 5 mg/day.

Claim **5** (original) The method of claim 4 wherein said composition is administered in an amount of about 0.5 to about 2.5 mg/day.

Claim **6** (original) The method of claim 5 wherein said composition is administered in an amount of about 0.5 to about 0.9 mg/day.

Claim **7** (original) The method of claim 6 wherein said composition is administered in an amount of about 0.5 to about 0.8 mg/day.

Claim **8** (original) The method of claim 7 wherein said composition is administered in an amount of about 0.5 to about 0.75 mg/day.

Claim **9** (original) The method of claim 1 wherein said composition is administered orally, topically, parenterally, transdermally, rectally, or vaginally.

Claim **10** (original) The method of claim 9 wherein said composition is orally administered, and further comprising a pharmaceutically acceptable carrier selected from the group consisting of a binder, diluent, lubricant, disintegrating agent, effervescing agent, dyestuff, sweetener, wetting agent, and mixtures thereof.

Claim **11** (original) The method of claim 10 wherein the oral administration is by a sachet, capsule, tablet, or aerosol spray.

Claim **12** (original) The method of claim 9 wherein said composition is parenterally administered subcutaneously, intraveously, or intramuscularly.

Claim **13** (original) The method of claim 1 wherein said compound comprises an optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, said compound being substantially free of (R,R) reboxetine.

Claim **14** (original) The method of claim 13 wherein the pharmaceutically acceptable salt is a methanesulfonate salt.

Claim **15** (original) The method of claim 13 wherein the optically pure (S,S) reboxetine or pharmaceutically acceptable salt thereof comprises at least about 90 wt.% of (S,S) reboxetine, and less than about 10 wt.% of (R,R) reboxetine, based on the total weight of the (S,S) and (R,R) reboxetine present.

Claim **16** (original) The method of claim 15 wherein the optically pure (S,S) reboxetine or pharmaceutically acceptable salt thereof comprises at least about 97 wt.% of (S,S) reboxetine and less than about 3 wt.% of (R,R) reboxetine, based on the total weight of the (S,S) and (R,R) reboxetine present.

Claim **17** (original) The method of claim 16 wherein the optically pure (S,S) reboxetine or pharmaceutically acceptable salt thereof comprises at least about 99 wt.% of (S,S) reboxetine and less than about 1 wt.% of (R,R) reboxetine, based on the total weight of the (S,S) and (R,R) reboxetine present.

Claims **18-31** (previously canceled)

Claim **32** (original) The method of claim 1 wherein the compound has a pharmacological selectivity of serotonin (K_i)/norepinephrine (K_i) of at least about 10,000.

Claim **33** (original) The method of claim 32 wherein the compound has a pharmacological selectivity of serotonin (K_i)/norepinephrine (K_i) of at least about 12,000.

Claim **34** (original) The method of claim 33 wherein the compound has a pharmacological selectivity of serotonin (K_i)/norepinephrine (K_i) of at least about 25,000.

Claim **35** (original) The method of claim 34 wherein the compound has a pharmacological selectivity of serotonin (K_i)/norepinephrine (K_i) of at least about 50,000.

Claim **36** (original) The method of claim 35 wherein the compound has a pharmacological selectivity of serotonin (K_i)/norepinephrine (K_i) of at least about 75,000.

Claim **37** (original) The method of claim 36 wherein the compound has a pharmacological selectivity of serotonin (K_i)/norepinephrine (K_i) of at least about 100,000.

Claim **38** (canceled)

Claim **39** (currently amended) A method of treating ~~treating~~ incontinence in an individual while diminishing adverse side effects, the method comprising the step of administering to the individual a total dose of about 0.1 to about 10 mg/day of an optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, said optically pure (S,S) reboxetine being substantially free of (R,R) reboxetine.

Claim **40** (original) The method of claim 39 wherein said adverse side effects comprise dizziness, insomnia, lightheadedness, changes in blood pressure, sweating, gastrointestinal disturbances, sexual dysfunction in males, anticholinergic-like effects, and side effects with drug-drug interactions.

Claim **41** (currently amended) A method of treating ~~or preventing~~ incontinence, the method comprising the step of administering a therapeutically effective dose of racemic reboxetine or a pharmaceutically acceptable salt thereof to an individual.

Claims **42-43** (previously canceled)

Claim **44** (original) The method of claim 41 wherein the reboxetine is administered to the individual in an amount of about 2 to about 20 mg/day.

Claim **45** (original) The method of claim 44 wherein the reboxetine is administered to the individual in an amount of about 4 to about 10 mg/day.

Claim **46** (original) The method of claim 45 wherein the reboxetine is administered to the individual in an amount of about 6 to about 10 mg/day.

Claim **47** (original) The method of claim 41 wherein said reboxetine is administered orally, parenterally, topically, transdermally, rectally, or vaginally.

Claim **48** (original) The method of claim 47 wherein said reboxetine is orally administered with a pharmaceutically acceptable carrier comprising at least one of a binder, diluent, lubricant, disintegrating agent, effervescing agent, dyestuff, sweetener, and wetting agent.

Claim **49** (original) The method of claim 48 wherein the oral administration is by a sachet, capsule, tablet, or aerosol spray.

Claim **50** (original) The method of claim 47 wherein said reboxetine is parenterally administered subcutaneously, intravenously, or intramuscularly.

Claim **51** (original) The method of claim 41 wherein the pharmaceutically acceptable salt is methanesulfonate salt.

Claims **52-53** (previously canceled)

Claim **54** (previously added) The method of claim 1, wherein incontinence is selected from the group consisting of stress incontinence, genuine stress incontinence, and mixed incontinence.

Claim **55** (canceled)

Claim **56** (previously added) The method of claim 39, wherein incontinence is selected from the group consisting of stress incontinence, genuine stress incontinence, and mixed incontinence.

Claim **57** (previously added) The method of claim 41, wherein incontinence is selected from the group consisting of stress incontinence, genuine stress incontinence, and mixed incontinence.